Skip to main content

CapForce Inc.

corporate_fare Company Profile

CapForce Inc.

CFOR·OTC·Trade & Services·CIK 0001293818

CapForce Inc. was incorporated in Delaware in 2001. From its inception through November 2023, the company operated as a precision medicine company. It utilized molecular diagnostics and informatics to address infectious diseases. The company, along with its subsidiaries Curetis GmbH and Ares Genetics GmbH, developed and commercialized molecular microbiology solutions. These solutions aimed to provide clinicians with faster and more actionable information on life-threatening infections, intending to improve patient outcomes and reduce the spread of infections caused by multidrug-resistant microorganisms (MDROs). In November 2023, CapForce Inc. implemented cash management initiatives, restructuring its U.S. operations by reducing headcount and scaling down its U.S. headquarters to core functions required for a U.S. Nasdaq listed company. Subsequently, Curetis and Ares Genetics filed for insolvency. As a result, insolvency administrators took control of their assets and liabilities, leading to the deconsolidation of these subsidiaries from CapForce Inc.'s financial statements. In April 2024, all of Curetis' assets were sold to Camtech Pte Ltd., and all of Ares Genetics' assets were sold to bioMerieux S.A. In March 2024, CapForce Inc. entered into a securities purchase agreement with David E. Lazar.

CapForce Inc. (OTC:CFOR) is a publicly traded company in the Trade & Services sector. Wiseek has independently scored 2 items for CFOR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-06, rated 7/10. Across its 2 most recent items scored 7 or higher, the top rating is 8/10, with 1 rated 8 or above. Recent SEC coverage for CFOR spans 8-K, 10-Q.

Recent high-impact activity:

  • CapForce Replaces CEO, COO and Adds Board Seat in Sweeping Management Reshuffle
  • CapForce Reports $50M Revenue Surge from Client B, But Cash Dwindles to $144K

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$30.2M
Net Income
$23.62M
Diluted EPS
$2.32
Op. Cash Flow
-$1.18M
Free Cash Flow
-$1.23M
Operating Income
$24.03M
Cash & Equivalents
$531.28K
Debt / Equity
0.00×
Net Margin
78.2%
Shares Outstanding
10.15M sh
Source: 10-K · filed 2026-05-26 · accession 0001829126-26-005672

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 87 shares in CFOR as of the October 30, 2026 settlement, a 2800.0% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On November 19, 2026, 42.0% of CFOR volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)87 shares as of October 30, 2026
Change vs prior period▲ 2800.0%
Days to cover1.00 at avg daily volume of 4,798
Daily short volume (FINRA facilities)42.0% of 1,059 shares on November 19, 2026
5-day average short volume15.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$4 -20.00% today
52-week range · as of 2026-11-06 $0.000001 – $34
Market cap
$49.85M
Volume
682 (0.4× avg)
3-mo avg 1.6K
Live data · 2026-11-20 20:56 UTC · Market open

show_chartPrice Chart

Loading chart...

feed CFOR - Latest Insights

CFOR
Nov 06, 2026, 5:08 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $6.80
Real-time Price: $4.00 info
Change: -$2.80 (-41%) info
Market Cap: $49.849M info
CFOR
Aug 19, 2026, 4:51 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.97
Real-time Price: $4.00 info
Change: +$1.03 (+35%) info
Market Cap: $49.849M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets